The role of cardiotrophin-1 in chronic heart failure
https://doi.org/10.21886/2219-8075-2023-14-4-108-113
Abstract
An analysis of the literature data on the role of the cardiotrophin-1 protein in chronic heart failure was carried out. Articles were selected and analyzed in PubMed, ScienceDirect, ProQuest, GoogleScholar, Cochrane, Medline, AMED, EMBASE, CINHAL, SportDiscus, Scopus and PEDro databases. The search for articles was carried out using the keywords: «Heart failure», «Biological markers», «Cardiotrophin-1», «Galectin-3», «Myocardium» and their combinations. Inclusion criteria were publication date from 2017 to 2022, clinical studies, meta-analyses and systematic reviews, randomized controlled trials, availability of the full text in the public domain or the abstract. Exclusion criteria: abstracts, monographs, textbooks, publication date before 2017, inconsistency with the research topic. A total of 80 publications were found. The review included 18 publications from 2017 to 2022 that corresponded to the topic and purpose of the study and were significant for revealing the subject of the study. Information is presented on the role of cardiotrophin-1 in chronic heart failure. Cardiotrophin-1 is activated in cardiac fibroblasts and cardiomyocytes in response to mechanical, humoral, metabolic and hypoxic stress. This biomarker is abundantly expressed in cardiac tissue and its overexpression is mainly stimulated by ventricular stretch/pressure, which promotes myocardial hypertrophy. Experimental administration of cardiotrophin-1 leads to fibrosis and myocardial remodeling, which indicates its role as a diagnostic biomarker in these pathologies and chronic heart failure in general.
About the Authors
L. R. Pakhnova
Astrakhan State Medical University
Russian Federation
Competing Interests:
Russian Federation
Liya R. Pakhnova – Cand. Sci (Med.), Assistant of the Department of Radiation Diagnostics
Astrakhan
Competing Interests:
Authors declares no conflict of interest
O. A. Bashkina
Astrakhan State Medical University
Russian Federation
Competing Interests:
Russian Federation
Olga A. Bashkina – Dr. Sci. (Med.), Professor, Rector, Head of the Department of Faculty Pediatrics
Astrakhan
Competing Interests:
Authors declares no conflict of interest
L. P. Voronina
Astrakhan State Medical University
Russian Federation
Competing Interests:
Russian Federation
Lyudmila P. Voronina – Dr. Sci. (Med.), Professor, Head of the Department of Department of Clinical Immunology with a Postgraduate Course
Astrakhan
Competing Interests:
Authors declares no conflict of interest
References
1. Lindmark K, Boman K, Olofsson M, Törnblom M, Levine A, et al. Epidemiology of heart failure and trends in diagnostic work-up: a retrospective, population-based cohort study in Sweden. Clin Epidemiol. 2019;11:231-244. https://doi.org/10.2147/CLEP.S170873
2. Agra RM, Fernandez-Trasancos A, Diaz-Rodriguez E, Cordero A, Varela-Román A, et al. Nu-trients restriction upregulates adiponectin in epicardial or subcutaneous adipose tissue: impact in de novo heart failure patients. Int J Med Sci. 2018;15(5):417-424. https://doi.org/10.7150/ijms.22854
3. Frangogiannis NG. The extracellular matrix in myocardial injury, repair, and remodeling. J Clin Invest. 2017;127(5):1600-1612. https://doi.org/10.1172/JCI87491
4. Ravassa S, López B, Querejeta R, Echegaray K, San José G, et al. Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome. J Hypertens. 2017;35(4):853-861. https://doi.org/10.1097/HJH.0000000000001258
5. Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCHCHF study. Kardiologiia. 2021;61(4):4-14. (In Russ.) https://doi.org/10.18087/cardio.2021.4.n1628
6. Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, et al. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2017;135(22):e1054-e1091. Erratum in: Circulation. 2017;136(19):e345. PMID: 28446515. https://doi.org/10.1161/CIR.0000000000000490
7. Ibrahim NE, Januzzi JL Jr. Established and Emerging Roles of Biomarkers in Heart Failure. Circ Res. 2018;123(5):614-629. https://doi.org/10.1161/CIRCRESAHA.118.312706
8. Martínez-Martínez E, Brugnolaro C, Ibarrola J, Ravassa S, Buonafine M, et al. CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation. Hypertension. 2019;73(3):602-611. https://doi.org/10.1161/HYPERTENSIONAHA.118.11874
9. Khosravi F, Ahmadvand N, Wartenberg M, Sauer H. Induction of Stem-Cell-Derived Cardiomyogenesis by Fibroblast Growth Factor 10 (FGF10) and Its Interplay with Cardiotrophin-1 (CT-1). Biology (Basel). 2022;11(4):534. https://doi.org/10.3390/biology11040534
10. Hogas S, Bilha SC, Branisteanu D, Hogas M, Gaipov A, et al. Potential novel biomarkers of cardiovascular dysfunction and disease: cardiotrophin-1, adipokines and galectin-3. Arch Med Sci. 2017;13(4):897-913. https://doi.org/10.5114/aoms.2016.58664
11. Abdul-Ghani M, Suen C, Jiang B, Deng Y, Weldrick JJ, et al. Cardiotrophin 1 stimulates beneficial myogenic and vascular remodeling of the heart. Cell Res. 2017;27(10):1195-1215. https://doi.org/10.1038/cr.2017.87
12. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-1356. https://doi.org/10.1002/ejhf.1858
13. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction.Circulation. 2018;138(9):861-870. https://doi.org/10.1161/CIRCULATIONAHA.118.034646
14. Sharif S, Saleem A, Naz S, Rashid F, Iqtedar M, et al. Increased Expression of Cardiotrophin-1 in Cardiomyopathy Patients. Balkan J Med Genet. 2021;24(1):21-26. https://doi.org/10.2478/bjmg-2021-0008
15. Vega RB, Konhilas JP, Kelly DP, Leinwand LA. Molecular Mechanisms Underlying Cardiac Adaptation to Exercise. Cell Metab. 2017;25(5):1012-1026. https://doi.org/10.1016/j.cmet.2017.04.025
16. Ping Y, Wang X, Dai Y, Wang D, Liu W, et al. A quantitative detection of Cardiotrophin-1 in chronic heart failure by chemiluminescence immunoassay. J Clin Lab Anal. 2021;35(4):e23570. https://doi.org/10.1002/jcla.23570
17. Ben Aissa A, Herrera-Chacon A, Pupin RR, Sotomayor MDPT, Pividori MI. Magnetic molecularly imprinted polymer for the isolation and detection of biotin and biotinylated biomolecules. Biosens Bioelectron. 2017;88:101-108. https://doi.org/10.1016/j.bios.2016.07.096
18. Gyöngyösi M, Winkler J, Ramos I, Do QT, Firat H, et al. Myocardial fibrosis: biomedical research from bench to bedside. Eur J Heart Fail. 2017;19(2):177-191. https://doi.org/10.1002/ejhf.696
19. Arrieta V, Martinez-Martinez E, Ibarrola J, Alvarez V, Sádaba R, et al. A role for galectin-3 in the development of early molecular alterations in short-term aortic stenosis. Clin Sci (Lond). 2017;131(10):935-949. https://doi.org/10.1042/CS20170145
20. Ionin V.A., Barashkova E.I., Pavlova V.A., Borisov G.I., Averchenko K.A., et al. What is the role of profibrogenic and proinflammatory factors in developing atrial fibrillation associated with metabolic syndrome components? Russian Journal of Cardiology. 2021;26(11):4752. (In Russ.) https://doi.org/10.15829/1560-4071-2021-4752
21. Ogurkova O.N., Pavlyukova E.N., Suslova T.E. Serum levels of cardiotrophin-1 in patients with obstructive hypertrophic cardiomyopathy and in patients with severe left ventricular dysfunction. The Siberian Journal of Clinical and Experimental Medicine. 2021;36(2):70-75. (In Russ.) https://doi.org/10.29001/2073-8552-2021-36-2-70-75
Review
For citations:
Pakhnova L.R., Bashkina O.A., Voronina L.P. The role of cardiotrophin-1 in chronic heart failure. Medical Herald of the South of Russia. 2023;14(4):108-113. (In Russ.) https://doi.org/10.21886/2219-8075-2023-14-4-108-113
Views:
297
Email this article 